DBVTF - Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies
COVID-19 Is Distracting Investors from an Amazing Market Opportunity
While the world remains hyper-focused on COVID-19 as the biggest healthcare challenge of the past century, it is perhaps easy to overlook progress being made to treat more mundane (yet far more durable) medical problems. A prime example is food allergies and the multi-billion dollar opportunity that exists for treating such conditions. Long after treatments and vaccines have relegated COVID-19 to the history books, society will continue to deal with the ever-growing scourge of food allergies.
Peanut allergies ((PA)) are among the most common and dangerous